Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Egis claims new anxiolytics with a favorable side effect profile

Sep. 27, 1996

Roche Bioscience-Signal drug discovery collaboration

Sep. 27, 1996

SNX-111 development re-scheduled

Sep. 27, 1996

Sanofi reports tachykinin antagonists

Sep. 27, 1996

Glutamate inhibitor progresses through the pipeline

Sep. 20, 1996

Another series of mGluR antagonists from Lilly

Sep. 20, 1996

Metabotropic glutamate receptor antagonists from Lilly

Sep. 20, 1996

Metabotropic glutamate antagonists from Novo Nordisk

Sep. 20, 1996

Forest prepares submission for Alzheimer's disease product

Sep. 20, 1996

Bayer patents new compounds for CNS disorders

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...